

ERRATA

In “Role of Antithymocyte Globulin and Granulocyte-Colony Stimulating Factor-Mobilized Bone Marrow in Allogeneic Transplantation for Patients with Hematologic Malignancies” (Chen et al, *Biol Blood Marrow Transplant* 2009;15:266-273) there was an error in the first paragraph of the “Conditioning Regimen” subsection of the “Patients and Methods” section. In the last sentence of this paragraph, the drug used was ATG-Fresenius, not ThymoglobulineTM. The corrected sentence is as follows: All patients received ATG-Fresenius (5 mg/kg per day; Fresenius, Germany) intravenously for 4 consecutive days, on days –5 to –2.

In the poster #280 titled, “Pre-emptive Treatment with Cidofovir for Symptomatic BK Virus Positive Patients Who Underwent Allogeneic Stem Cell Transplant Reduces the Risk of Progression to Hemorrhagic Cystitis” (Bilodeau et al, *Biol Blood Marrow Transplant* 2009;15/2S:102) there was a dosing error in the second column, line 13. “... subsequently received Cidofovir 375 mg i.v. QOW...” is corrected as follows, “... subsequently received Cidofovir 0.2 mg/kg i.v. QOW...”.